
Whether you prefer growth stocks, value stocks, dividend stocks, or a mixture of investments in your portfolio, price should only be one factor you consider when determining which businesses to add.
Dividends can be a great way to increase your returns with time while giving you extra capital to reinvest or keep in your portfolio. These kinds of stocks can be found across many different sectors and industries.
Are You Missing The Morning Scoop? Wake up with Breakfast news in your inbox every market day. Sign Up For Free »
If you’re looking for two top dividend stocks to consider for your portfolio and have $500 available to invest, read on.
Johnson & Johnson (NYSE: JNJ) is one of the largest pharmaceutical businesses in the world, and it’s used that status to help drive favorable investor returns many times through the years. The company is one of a handful of businesses with a track record of not only paying but raising its dividend for more than 50 years.
In the case of Johnson & Johnson, the healthcare giant has increased its dividend every year for 62 years in a row. At the time of this writing, the stock yields approximately 3.2%, which is considerably more than the 1.3% the average company trading on the S&P 500 yields. From a forward annual dividend perspective, investors can expect a payout of $4.96 per share.
Johnson & Johnson also maintains a payout ratio of 80% of earnings. With its various businesses raking in $20 billion in free cash flow and $25 billion in operating cash flow over the trailing 12 months alone, it’s safe to say that the company is financially sound enough to continue paying dividends to investors.
To be clear, J&J is dealing with ongoing talc-related litigation that has been a consideration for years at this point. While the outcome of these cases is pending and could cost the company millions in settlement damages, J&J has already set aside sufficient funds to meet these obligations and still honor its dividend commitment to shareholders.
Looking at results for the third quarter of 2024, Johnson & Johnson reported net sales of $22.4 billion, a 5% increase from the same period one year ago. The company also brought in net earnings of $2.7 billion on that amount. Both its innovative medicine and medtech segments grew net sales by similar clips from one year ago — about 5% and 6%, respectively. Investors looking for a reliable income stock to buy and hold for the long haul may want to consider this no-brainer buy.